Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience
| Autor: | M. P. Delaney, D. C. Dukes, M. E. Edmunds |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male medicine.medical_specialty Nephrotic Syndrome medicine.medical_treatment Gastroenterology Internal medicine Cyclosporin a medicine Humans Minimal change disease Aged Retrospective Studies Chemotherapy Proteinuria business.industry Glomerulosclerosis Glomerulonephritis General Medicine Middle Aged medicine.disease Endocrinology Cyclosporine Mesangial proliferative glomerulonephritis Female Immunotherapy medicine.symptom business Nephrotic syndrome Research Article |
| Popis: | Summary The use of cyclosporin A (Cy A) in idiopathic nephrotic syndrome, particularly lesions of focal segmental glomerular sclerosis, is controversial. A retrospective study of 10 adult patients with nephrotic syndrome treated with Cy A was performed. Histological diagnosis was established in all patients: focal segmental glomerular sclerosis (n = 6), focal global sclerosis (n = 1), mesangial proliferative glomerulonephritis (n = 1), focal proliferative glomerulonephritis (n = 1) and minimal change disease (n = 1). All patients had previously received immunosuppressive therapy (duration of steroids 1-76 months; 35.0 +/- 12.1, mean +/- SEM). Cy A in a dose of 3-5 mg/kg/day, reduced proteinuria from 16.85 +/- 6.67 to 3.37 +/- 1.48 g/24 hours (P = 0.008), with an associated increase in serum albumin from 15.2 +/- 2.6 to 34.3 +/- 2.5 g/l (P < 0.001). In six patients steroid therapy was discontinued. Cy A was well tolerated for up to 5 years. There was no significant nephrotoxicity. In conclusion, Cy A was effective treatment of refractory idiopathic nephrotic syndrome, including those cases with focal segmental glomerular sclerosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|